A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
The purpose of this study is to assess the safety and efficacy of rovalpituzumab tesirine administered in combination with nivolumab or nivolumab and ipilimumab in participants with extensive-stage small cell lung cancer (SCLC).
Checked against the public recordLast updated Jul 17, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- AbbVie
- Interventions being studied
- Drug: Ipilimumab; Drug: Nivolumab; Drug: Rovalpituzumab tesirine
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Participants with histologically or cytologically confirmed extensive-stage small cell lung cancer (SCLC) with progressive disease after at least one platinum-based chemotherapeutic regimen and with evaluable or measurable disease * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate hematologic, hepatic, and renal function Exclusion Criteria: * Has active, known, or suspected autoimmune disease * Had prior exposure to an immuno-oncology or pyrrolobenzodiazepine (PBD)-based drug
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Ucsd /Id# 161030La Jolla, California
- Florida Hospital /ID# 161017Orlando, Florida
- University Cancer & Blood Cent /ID# 161028Athens, Georgia
- University of Chicago /ID# 161006Chicago, Illinois
- The University of Kansas Clini /ID# 162915Fairway, Kansas
- Washington University-School of Medicine /ID# 161011St Louis, Missouri
- Rutgers Cancer Institute of NJ /ID# 161032New Brunswick, New Jersey
- Memorial Sloan Kettering Cancer Center /ID# 161010New York, New York
- Duke University Medical Center /ID# 161009Durham, North Carolina
- Oregon Health and Science University /ID# 161029Portland, Oregon
- Medical University of South Carolina /ID# 161007Charleston, South Carolina
- Tennessee Oncology, PLLC /ID# 161012Nashville, Tennessee
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 17, 2020. Always confirm current availability with the study team.